{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:29:53Z","timestamp":1772166593410,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-024-02657-3","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T03:03:46Z","timestamp":1737687826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2732-1731","authenticated-orcid":false,"given":"Jack","family":"Wilson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Langcake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom P.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janni","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary C. K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Englund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myfanwy","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Stockings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"2","key":"2657_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11920-019-0997-0","volume":"21","author":"J Rehm","year":"2019","unstructured":"Rehm J, Shield KD. Global burden of disease and the impact of mental and addictive disorders. Curr Psychiatry Rep. 2019;21(2):10.","journal-title":"Curr Psychiatry Rep"},{"issue":"3","key":"2657_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/wps.20457","volume":"16","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Glantz M, Evans-Lacko S, Sadikova E, Sampson N, Thornicroft G, et al. Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys. World Psychiatry. 2017;16(3):299\u2013307.","journal-title":"World Psychiatry"},{"issue":"1","key":"2657_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/wps.20482","volume":"17","author":"AM Kilbourne","year":"2018","unstructured":"Kilbourne AM, Beck K, Spaeth-Rublee B, Ramanuj P, O\u2019Brien RW, Tomoyasu N, et al. Measuring and improving the quality of mental health care: a global perspective. World Psychiatry. 2018;17(1):30\u20138.","journal-title":"World Psychiatry"},{"key":"2657_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S2352-4642(18)30342-0","volume":"3","author":"J Wilson","year":"2018","unstructured":"Wilson J, Freeman TP, Mackie CJ. Effects of increasing cannabis potency on adolescent health. Lancet Child Adolesc Health. 2018;3:121\u2013218.","journal-title":"Lancet Child Adolesc Health"},{"key":"2657_CR5","unstructured":"Therapeutic Goods Administration. Medicinal Cannabis authorised prescriber patient data 2023. Available from: https:\/\/dashboard-data.health.gov.au\/single\/?appid=f330a1c6-d805-4c64-a6ef-76a69d32d8b7&sheet=a7cdc199-1658-4c94-87d0-9a3b76c520eb&select=clearall."},{"issue":"5","key":"2657_CR6","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00213-021-06047-8","volume":"239","author":"J Leung","year":"2022","unstructured":"Leung J, Chan G, Stjepanovi\u0107 D, Chung JYC, Hall W, Hammond D. Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada. Psychopharmacology. 2022;239(5):1509\u201319.","journal-title":"Psychopharmacology"},{"key":"2657_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-030-21737-2_8","volume":"1162","author":"MR Amin","year":"2019","unstructured":"Amin MR, Ali DW. Pharmacology of medical cannabis. Adv Exp Med Biol. 2019;1162:151\u201365.","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"2657_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/jnnp-2017-317168","volume":"89","author":"E Stockings","year":"2018","unstructured":"Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry. 2018;89(7):741\u201353.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"2657_CR9","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","volume":"6","author":"N Black","year":"2019","unstructured":"Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995\u20131010.","journal-title":"Lancet Psychiatry"},{"key":"2657_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jep.2018.09.004","volume":"227","author":"SA Bonini","year":"2018","unstructured":"Bonini SA, Premoli M, Tambaro S, Kumar A, Maccarinelli G, Memo M, et al. Cannabis sativa: a comprehensive ethnopharmacological review of a medicinal plant with a long history. J Ethnopharmacol. 2018;227:300\u201315.","journal-title":"J Ethnopharmacol"},{"key":"2657_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2013.00129","volume":"4","author":"B Chadwick","year":"2013","unstructured":"Chadwick B, Miller ML, Hurd YL. Cannabis use during adolescent development: susceptibility to psychiatric illness. Front Psychiatry. 2013;4:1\u20138.","journal-title":"Front Psychiatry"},{"issue":"4","key":"2657_CR12","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s10787-022-01020-z","volume":"30","author":"JD Henson","year":"2022","unstructured":"Henson JD, Vitetta L, Hall S. Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions. Inflammopharmacology. 2022;30(4):1167\u201378.","journal-title":"Inflammopharmacology"},{"issue":"9","key":"2657_CR13","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.tips.2011.05.004","volume":"32","author":"E Keimpema","year":"2011","unstructured":"Keimpema E, Mackie K, Harkany T. Molecular model of cannabis sensitivity in developing neuronal circuits. Trends Pharmacol Sci. 2011;32(9):551\u201361.","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"2657_CR14","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1039\/C6NP00074F","volume":"33","author":"LO Hanu\u0161","year":"2016","unstructured":"Hanu\u0161 LO, Meyer SM, Mu\u00f1oz E, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33(12):1357\u201392.","journal-title":"Nat Prod Rep"},{"issue":"3","key":"2657_CR15","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","volume":"35","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. Opposite Effects of \u0394-9-tetrahydrocannabinol and Cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35(3):764\u201374.","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"2657_CR16","doi-asserted-by":"publisher","first-page":"e00682","DOI":"10.1002\/prp2.682","volume":"8","author":"DL de Almeida","year":"2020","unstructured":"de Almeida DL, Devi LA. Diversity of molecular targets and signaling pathways for CBD. Pharmacol Res Perspect. 2020;8(6):e00682.","journal-title":"Pharmacol Res Perspect"},{"key":"2657_CR17","doi-asserted-by":"publisher","first-page":"204512531988191","DOI":"10.1177\/2045125319881916","volume":"9","author":"C Davies","year":"2019","unstructured":"Davies C, Bhattacharyya S. Cannabidiol as a potential treatment for psychosis. Ther Adv Psychopharmacol. 2019;9:2045125319881916.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"11","key":"2657_CR18","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","volume":"75","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya S, Wilson R, Appiah-Kusi E, O\u2019Neill A, Brammer M, Perez J, et al. Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. JAMA Psychiat. 2018;75(11):1107\u201317.","journal-title":"JAMA Psychiat"},{"issue":"4","key":"2657_CR19","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.3390\/ijms22041863","volume":"22","author":"PA Melas","year":"2021","unstructured":"Melas PA, Scherma M, Fratta W, Cifani C, Fadda P. Cannabidiol as a potential treatment for anxiety and mood disorders: molecular targets and epigenetic insights from preclinical research. Int J Mol Sci. 2021;22(4):1863.","journal-title":"Int J Mol Sci"},{"key":"2657_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neuropharm.2017.05.031","volume":"124","author":"ME Sloan","year":"2017","unstructured":"Sloan ME, Gowin JL, Ramchandani VA, Hurd YL, Le Foll B. The endocannabinoid system as a target for addiction treatment: trials and tribulations. Neuropharmacology. 2017;124:73\u201383.","journal-title":"Neuropharmacology"},{"issue":"10","key":"2657_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","volume":"7","author":"TP Freeman","year":"2020","unstructured":"Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020;7(10):865\u201374.","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"2657_CR22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","volume":"176","author":"YL Hurd","year":"2019","unstructured":"Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry. 2019;176(11):911\u201322.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"2657_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/da.22217","volume":"31","author":"R Uher","year":"2014","unstructured":"Uher R, Payne JL, Pavlova B, Perlis RH. Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depress Anxiety. 2014;31(6):459\u201371.","journal-title":"Depress Anxiety"},{"issue":"2","key":"2657_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","volume":"9","author":"GBD 2019 Mental Disorders Collaborators","year":"2022","unstructured":"GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137\u201350.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"2657_CR25","first-page":"042","volume":"6","author":"G Perrotta","year":"2019","unstructured":"Perrotta G. Anxiety disorders: definitions, contexts, neural correlates and strategic therapy. J Neur Neurosci. 2019;6(1):042.","journal-title":"J Neur Neurosci"},{"issue":"1","key":"2657_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.encep.2019.06.005","volume":"46","author":"S Weibel","year":"2020","unstructured":"Weibel S, Menard O, Ionita A, Boumendjel M, Cabelguen C, Kraemer C, et al. Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder (ADHD) in adults. Enc\u00e9phale. 2020;46(1):30\u201340.","journal-title":"Enc\u00e9phale"},{"issue":"8","key":"2657_CR27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","volume":"27","author":"RE Cooper","year":"2017","unstructured":"Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit\/hyperactivity disorder: a randomised-controlled trial. Eur Neuropsychopharmacol. 2017;27(8):795\u2013808.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2657_CR28","first-page":"1","volume":"2019","author":"G Perrotta","year":"2019","unstructured":"Perrotta G. Tic disorder: definition, clinical contexts, differential diagnosis, neural correlates and therapeutic approaches. J Neurosci Rehab. 2019;2019:1\u20136.","journal-title":"J Neurosci Rehab"},{"key":"2657_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.pediatrneurol.2022.08.010","volume":"137","author":"F Jafari","year":"2022","unstructured":"Jafari F, Abbasi P, Rahmati M, Hodhodi T, Kazeminia M. Systematic review and meta-analysis of tourette syndrome prevalence; 1986 to 2022. Pediatr Neurol. 2022;137:6\u201316.","journal-title":"Pediatr Neurol"},{"issue":"8","key":"2657_CR30","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41386-020-0671-6","volume":"45","author":"KR M\u00fcller-Vahl","year":"2020","unstructured":"M\u00fcller-Vahl KR, Bindila L, Lutz B, Musshoff F, Skripuletz T, Baumgaertel C, et al. Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome. Neuropsychopharmacology. 2020;45(8):1323\u20139.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"2657_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/wps.20656","volume":"18","author":"RA Bryant","year":"2019","unstructured":"Bryant RA. Post-traumatic stress disorder: a state-of-the-art review of evidence and challenges. World Psychiatry. 2019;18(3):259\u201369.","journal-title":"World Psychiatry"},{"issue":"5","key":"2657_CR32","doi-asserted-by":"publisher","first-page":"426","DOI":"10.30773\/pi.2020.0458","volume":"18","author":"L Zhang","year":"2021","unstructured":"Zhang L, Pan R, Cai Y, Pan J. The prevalence of post-traumatic stress disorder in the general population during the COVID-19 pandemic: a systematic review and single-arm meta-analysis. Psychiatry Investig. 2021;18(5):426\u201333.","journal-title":"Psychiatry Investig"},{"key":"2657_CR33","doi-asserted-by":"publisher","first-page":"107551","DOI":"10.1016\/j.pharmthera.2020.107551","volume":"211","author":"B Sbarski","year":"2020","unstructured":"Sbarski B, Akirav I. Cannabinoids as therapeutics for PTSD. Pharmacol Ther. 2020;211:107551.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"2657_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/wps.20959","volume":"21","author":"P Fusar-Poli","year":"2022","unstructured":"Fusar-Poli P, Estrad\u00e9 A, Stanghellini G, Venables J, Onwumere J, Messas G, et al. The lived experience of psychosis: a bottom-up review co-written by experts by experience and academics. World Psychiatry. 2022;21(2):168\u201388.","journal-title":"World Psychiatry"},{"issue":"4","key":"2657_CR35","doi-asserted-by":"publisher","first-page":"e0195687","DOI":"10.1371\/journal.pone.0195687","volume":"13","author":"B Moreno-K\u00fcstner","year":"2018","unstructured":"Moreno-K\u00fcstner B, Mart\u00edn C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS One. 2018;13(4):e0195687.","journal-title":"PLOS ONE"},{"issue":"7","key":"2657_CR36","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.biopsych.2015.11.018","volume":"79","author":"FM Leweke","year":"2016","unstructured":"Leweke FM, Mueller JK, Lange B, Rohleder C. Therapeutic potential of cannabinoids in psychosis. Biol Psychiat. 2016;79(7):604\u201312.","journal-title":"Biol Psychiat"},{"issue":"1","key":"2657_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31579\/2578-8868\/097","volume":"5","author":"G Perrotta","year":"2019","unstructured":"Perrotta G. Bipolar disorder: definition, differential diagnosis, clinical contexts and therapeutic approaches. J Neurosci Neurol Surg. 2019;5(1):1\u20136. https:\/\/doi.org\/10.31579\/2578-8868\/097.","journal-title":"J Neurosci Neurol Surg"},{"issue":"3","key":"2657_CR38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/add.14776","volume":"115","author":"E Kroon","year":"2020","unstructured":"Kroon E, Kuhns L, Hoch E, Cousijn J. Heavy cannabis use, dependence and the brain: a clinical perspective. Addiction. 2020;115(3):559\u201372.","journal-title":"Addiction"},{"issue":"12","key":"2657_CR39","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","volume":"5","author":"L Degenhardt","year":"2018","unstructured":"Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987\u20131012.","journal-title":"Lancet Psychiatry"},{"key":"2657_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fpsyt.2019.00063","volume":"10","author":"Y Chye","year":"2019","unstructured":"Chye Y, Christensen E, Solowij N, Y\u00fccel M. The endocannabinoid system and Cannabidiol\u2019s promise for the treatment of substance use disorder. Front Psychiatry. 2019;10:63.","journal-title":"Front Psychiatry"},{"issue":"9","key":"2657_CR41","doi-asserted-by":"publisher","first-page":"eaax4043","DOI":"10.1126\/sciadv.aax4043","volume":"5","author":"K Witkiewitz","year":"2019","unstructured":"Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv. 2019;5(9):eaax4043.","journal-title":"Sci Adv"},{"issue":"2","key":"2657_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/ajad.12862","volume":"28","author":"TR Kosten","year":"2019","unstructured":"Kosten TR, Baxter LE. Review article: effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment. Am J Addict. 2019;28(2):55\u201362.","journal-title":"Am J Addict"},{"issue":"4","key":"2657_CR43","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/add.15703","volume":"117","author":"NL Benowitz","year":"2022","unstructured":"Benowitz NL, Liakoni E. Tobacco use disorder and cardiovascular health. Addiction. 2022;117(4):1128\u201338.","journal-title":"Addiction"},{"issue":"10","key":"2657_CR44","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1111\/add.14234","volume":"113","author":"A Peacock","year":"2018","unstructured":"Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction. 2018;113(10):1905\u201326.","journal-title":"Addiction"},{"key":"2657_CR45","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: Author; 2013.","edition":"5"},{"key":"2657_CR46","unstructured":"Covidence systematic review software VHI, Melbourne, Australia. Available from: www.covidence.org. Accessed\u00a016 Sep 2023."},{"key":"2657_CR47","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"5","key":"2657_CR48","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1398-9995.2009.01973.x","volume":"64","author":"JL Brozek","year":"2009","unstructured":"Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64(5):669\u201377.","journal-title":"Allergy"},{"key":"2657_CR49","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. 2011;343:d5928.","DOI":"10.1136\/bmj.d5928"},{"issue":"10","key":"2657_CR50","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1097\/j.pain.0000000000001293","volume":"159","author":"E Stockings","year":"2018","unstructured":"Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159(10):1932\u201354.","journal-title":"Pain"},{"key":"2657_CR51","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1089\/can.2023.0065","volume":"8","author":"JAB Fernandes","year":"2023","unstructured":"Fernandes JAB, Filev R, Fidalgo TM. Cannabinoids for substance use disorder treatment: what does the current evidence say? Cannabis Cannabinoid Res. 2023;8:703\u201315.","journal-title":"Cannabis Cannabinoid Res"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-024-02657-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-024-02657-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-024-02657-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T03:37:23Z","timestamp":1737689843000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-024-02657-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2657"],"URL":"https:\/\/doi.org\/10.1186\/s13643-024-02657-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3250418\/v1","asserted-by":"object"}]},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"9 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics and consent were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consented to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}